Vaccine Adjuvants Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DM1707 | Last Updated On: Jun 14 2022 | Available Formats

> Global Vaccine Adjuvants Market Expected to reach a high CAGR of ~12.5% By 2029: DataM Intelligence

Global Vaccine Adjuvants Market is segmented By Product (Adjuvant Emulsions, Pathogen Components, Particulate Adjuvants, Combination Adjuvants), By Route of Administration (Oral, Intramuscular, Intranasal, Subcutaneous, Intradermal), By Disease (Cancer and Infectious Diseases), By End User (Research and Commercial Applications), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 

Vaccine Adjuvants Market Trends Size Growth Insights

The Vaccine Adjuvants Market size was valued at USD XX billion in 2021, it is expected to reach USD XX billion by the end of 2029, with growth at a CAGR of ~12.5% during the forecasting period 2022-2029. An adjuvant is an ingredient used in some vaccines to enhance host immune responses in people receiving the vaccine. Vaccines are among the most effective preventative health tools available against infectious diseases, cancer, allergy, and autoimmune diseases. Vaccination aims to generate a strong immune response to the administrated antigen and provide long-term protection against disease. Frequently, using only the antigen is not enough to stimulate that protective immunity. Vaccine adjuvants are compounds that enhance the specific immune responses against co-administered antigens in vaccines.

According to the research analysis, the global market report covered several countries such as the USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Spain, Italy, France, London, Russia, Ukraine, UAE, KSA, Qatar, Middle east countries, South Africa, India, Japan, China, Australia, Singapore, Malaysia, Korea, and Other major countries covered in the research report. Apart from all regions, the North American region has the largest share in the global Vaccine Adjuvants Market share over the forecast period, and this region remains its control over the global market. Europe Vaccine Adjuvants Market is projected to produce the second-largest share in the global market over the forecast period 2022-2029. And Asia Pacific region is estimated to show the highest growth rate over the forecast period of 2029.

According to the report published by the DataM Intelligence, the global Vaccine Adjuvants Market segmentation includes the product, route of administration, disease, and end-user.  Based on the product segment, the particulate adjuvants are anticipated to grasp the controlling market share throughout the forecast period 2022-2029. The Vaccine Adjuvants Market report contains major key player's strategies, company profile analysis, market drivers, restraints, opportunities, challenges, recent developments in the Vaccine Adjuvants industry, market volume, market demand, and market growth outlook analysis over the forecast period 2022-2029.

Market Dynamics

The vaccine adjuvants market growth is driven by several factors, such as the high prevalence of infectious diseases, increased government funding for research, and growing focus on preventing diseases.

Globally the incidence of infectious diseases has major health and economic costs. Infectious diseases are caused by bacteria, viruses, parasites, or fungi. Infectious diseases are communicable as well. The number of infectious disease outbreaks has risen steadily in the last 30 years. According to the World Health Organization (WHO), infectious diseases kill more than 17 million people a year. 30 new diseases have emerged in the last 20 years. Vaccines improve immunity to a particular disease and are a vital part of infectious disease prevention. One of the most cost-effective investments in health and economic development WHO estimates that 1.5 million children under the age of five lose their lives to vaccine-preventable diseases every year.

Many government agencies are working towards new research in vaccine adjuvants and raising enough funds for the new advancements. The National Institute of Allergy and Infectious Diseases (NIAID) support aspects of adjuvant research. NIAID recognized opportunities to develop novel adjuvants or modify existing adjuvants to trigger long-term protective immunity and durable vaccine efficacy safely. In 2010, NIAID prepared its first Strategic Plan for Research on Vaccine Adjuvants and convened an Adjuvant Blue Ribbon Panel (BRP) to review the plan. Furthermore, National Biopharma Mission, in collaboration with NIAID, is providing research grants for the discovery, development, and/or preclinical testing of vaccine adjuvants under the aegis of Indo US Vaccine Action Programme (VAP).  VAP is one of the oldest bilateral programs that support a wide range of collaborative activities related to immunology drugs, infectious disease biology, and vaccine research.

Vaccine Adjuvants Market Scope

Metrics

Details

Market CAGR

12.5%

Segments Covered

By Product, By Route of Administration, By Disease, By End-user, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

Market Segmentation

The global vaccine adjuvants market is segmented into adjuvant emulsions, pathogen components, particulate adjuvants, combination adjuvants, and others by product type. Emulsion-based adjuvants are oil-in-water or water-in-oil emulsions, which work to enable the slow release of an antigen at the injection site. MF59 and AS03 are two licensed oil-in-water emulsion adjuvants used in humans. MF59 is not toxic and prepared with a low squalene content, a biodegradable oil naturally found in plants and animals, including humans. Pathogen-based vaccine adjuvants are adjuvants that are derived from different pathogens. Bacteria have an abundance of capacity for stimulating the immune system, and the adjuvants derived from bacteria are abundant.

As whole bacteria are generally too toxic to use as an adjuvant, many bacterium-derived vaccine adjuvants are derived from parts of bacteria. Only two of the pathogen-based adjuvants are licensed. One is MPL licensed in the U.S. as part of the AS04 adjuvant formulation, and Bordetella pertussis component vaccine adjuvant is used in several licensed vaccines. Particulate antigen delivery systems are adjuvants that have a depot effect for the antigen and include liposomes, polymeric microspheres, virus-like particles, and immunostimulating complexes. These adjuvants act as vehicles for the antigen while often also containing immunostimulating compounds. Combination vaccine adjuvants include two or more different adjuvants that are used in combination. Examples of combination adjuvants include adjuvants such as AS04 and Algammulin. These adjuvants combine different mechanisms of action from two or more adjuvants.

Among these, particulate adjuvants are expected to hold the dominant market share over the period forecast (2020-2027). Particulate type adjuvants consist of alum, virosomes, and cytokines. Alum is the most commonly used and the most efficient adjuvant consisting of aluminum salts. It is found in numerous vaccines, including diphtheria-tetanus-pertussis, human papillomavirus, and hepatitis vaccines.

The market is segmented into oral, intramuscular, intranasal, subcutaneous, and intradermal by route of administration. Among these, intramuscular is expected to hold the highest market share during the forecast period (2020-2027) due to a large number of adjuvants being effective only when taken intramuscularly, such as alum adjuvants. Alum adjuvants have the highest market share, and they are only effective with the intramuscular route of administration.

Based on disease type, the market is segmented into cancer, infectious diseases, and others. Among these infectious diseases, the segment is expected to hold the largest market share over the period forecast (2020-2027) due to the rising prevalence of infectious diseases globally as an epidemic. Many new infectious diseases have been discovered in the last 20 years, such as Ebola, Zika, and many more. Vaccines are the most efficient treatment for infectious diseases.

By end-users, the market is segmented as pharmaceutical and biotech companies, research institutes, and others. Pharmaceutical and biotech companies are expected to be the largest shareholder in the market over the period forecast (2020-2027). Many new companies and existing companies in the market segment are working on new research in the area of vaccine adjuvants. This is due to large government funding for new research and development of technology.

Geographical Analysis

North America is dominating the vaccine adjuvants market in 2018 and is estimated to hold the largest market size over the forecast period (2020-2027), owing to the highly aware public, favorable government initiatives and policies, and an increase in research and development. The US government supports vaccine adjuvants through various government bodies, like the National Institute of Allergy and Infectious Diseases, which supports the work on new research and development, and provides funds to different countries through its parent organization National Institute of Health (NIH). NIH is collaborating with many research institutes and universities to fasten up the research of new vaccine adjuvants. Many companies present in the region are also developing many new vaccine adjuvants. There is a presence of many major companies in the region that focus on the parent region.

Competitive Landscape

Some of the major key players in the market are Croda International Plc, CSL Limited, SEPPIC, Agenus, Inc., Novavax, Inc., SPI Pharma, Inc., Invivogen, Avanti Polar Lipids, Inc., Valneva, and OZ Biosciences.

In the vaccine adjuvants market, the key players are adopting various growth strategies such as new product launches, partnerships, and collaborations with multiple research institutes and increasing research and development and high investment, contributing to the growth of the vaccine adjuvants market globally.

Target Audience

Trending Topics

Vaccine Refrigerators Market

Vaccines Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

Discount Applied



25% discount offer

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest